

Literatur für onkologie heute 08/2021

SCHWERPUNKT: Prostatakarzinom

Prostatabiopsie mit Ultraschall und MRT (S. 20–23)

H. Cash

1. Kasivisvanathan V et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. *N Engl J Med* 2018; 378(19): 1767–77
 2. Drost FH et al. Prostate Magnetic Resonance Imaging, with or Without Magnetic Resonance Imaging-targeted Biopsy, and Systematic Biopsy for Detecting Prostate Cancer: A Cochrane Systematic Review and Meta-analysis. *EurUrol* 2020; 77(1): 78–94
 3. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Prostatakarzinom, Langversion 6.0, 2021, AWMF Reg.-Nr.: 043/022OL, <http://www.leitlinienprogrammmonkologie.de/leitlinien/prostatakarzinom/> (abgerufen am: 04.07.2021)
 4. <https://uroweb.org/guideline/prostate-cancer>
 5. Ahmed HU et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. *Lancet* 2017; 389(10071): 815–22
 6. van der Leest M et al. High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility. *Eur Urol* 2019; 76(5): 574–81
 7. <https://www.acr.org/-/media/ACR/Files/RADS/Pi-RADS/PIRADS-V2-1.pdf?la=en>
 8. Costa DN et al. Prospective PI-RADS v2.1 A typical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI. *AJR Am J Roentgenol* 2021; 1–9
 9. Maxeiner A et al. Primarymagnetic resonance imaging/ultrasonography fusion-guidedbiopsyof theprostate. *BJU Int* 2018; 122(2): 211–18
 10. Hansen NL et al. Optimising the number of cores for magnetic resonance imaging-guided targeted and systematic transperineal prostate biopsy. *BJU Int* 2020; 125(2): 260–69
 11. Günzel K et al. Infection rate and complications after 621 transperineal MRI-TRUS fusion biopsies in local anesthesia without standard antibiotic prophylaxis. *World J Urol* 2021. doi: 10.1007/s00345-021-03699-1
 12. Cornud F et al. MRI-directed high-frequency (29Mhz) TRUS-guided biopsies: initial results of a single-center study. *Eur Radiol* 2020
 13. Rodríguez Socarrás ME et al. Prostate Mapping for Cancer Diagnosis: The Madrid Protocol. Transperineal Prostate Biopsies Using mpMRI Fusion and Micro-ultrasound Guided Biopsies. *J Urol* 2020
 14. Lughezzani G et al. Comparison of the Diagnostic Accuracy of Micro-ultrasound and Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsies for the Diagnosis of Clinically Significant Prostate Cancer. *Eur Urol Oncol* 2019; 2(3): 329–32
 15. Wiemer L et al. Evolution of Targeted Prostate Biopsy by Adding Micro-Ultrasound to the Magnetic Resonance Imaging Pathway. *Eur Urol Focus* 2020
-

Die Therapie des mCRPC: Ansätze heute und Zukunftsvisionen – Der Wunsch nach personalisierter Therapie (S.35–41)

K. Kornienko, M. De Santis, T. Schlomm

1. Haffner MC et al. Genomic and phenotypic heterogeneity in prostate cancer. *Nat Rev Urol* 2020; 18(2): 79–92
2. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). Berlin. 2020. In: Krebsdaten – Zentrum für Krebsregisterdaten [Internet]. [cited 04/2021]. Available: https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2019/krebs_in_deutschland_2019.pdf
3. Labriola MK et al. Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies. *Prostate Cancer Prostatic Dis* 2021; 24: 301–9
4. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. *Int J Clin Pract* 2011; 65(11): 1180–92
5. Tannock IF et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *N Engl J Med* 2004; 351: 1502–12
6. Ryan CJ et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. *Lancet Oncol* 2015; 16: 152–60
7. Beer TM et al. Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med* 2014; 371: 424–33
8. de Bono J et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. *N Engl J Med* 2020; 382: 2091–102
9. Hussain M et al. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. *N Engl J Med* 2020; 383: 2345–57
10. Cornford P et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. *Eur Urol* 2021; 79: 263–82
11. Rebello RJ et al. Prostate cancer. *Nat Rev Dis Primers* 2021; 7: 9
12. Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. 2021. Available: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Prostatakarzinom/Version_6/LL_Prostatakarzinom_Langversion_6.01.pdf
13. Gravis G et al. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. *Eur Urol* 2018; 73: 847–55
14. Abidi A. Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects. *J Pharmacol Pharmacother* 2013; 4: 230–7
15. Bono JS de et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. *Lancet* 2010; 376(9747): 1147–54
16. de Wit R et al. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. *N Engl J Med* 2019; 381: 2506–18
17. Eisenberger M et al. Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m²) and the Currently Approved Dose (25 mg/m²) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA. *J Clin Oncol* 2017; 35(28): 3198–206

18. Li Z et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. *Nature* 2015; 523: 347–51
19. Briones Carvajal JR et al. Real-world comparison of abiraterone (A) versus enzalutamide (E) for first-line therapy of metastatic castration-resistant prostate cancer (mCRPC). *J Clin Orthod* 2021; 39: 133
20. Chowdhury S et al. Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry. *Target Oncol* 2020; 15(3): 301–15
21. Rathkopf DE et al. Final results from ACIS, a randomized, placebo (PBO)-controlled double-blind phase 3 study of apalutamide (APA) and abiraterone acetate plus prednisone (AAP) versus AAP in patients (pts) with chemo-naïve metastatic castration-resistant prostate cancer (mCRPC). *J Clin Orthod* 2021; 39: 9
22. Armstrong AJ et al. Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial. *J Clin Oncol* 2019. #687. doi:10.1200/jco.2019.37.7_suppl.687
23. Khalaf DJ et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. *Lancet Oncol* 2019; 20: 1730–39
24. Parker C et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. *N Engl J Med* 2013; 369: 213–23
25. Smith M et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2019; 20: 408–19
26. Hofman MS et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. *Lancet* 2021; 397: 797–804
27. Morris MJ et al. Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION). *J Clin Oncol* 2021. #LBA4. doi:10.1200/jco.2021.39.15_suppl.lba4
28. Pritchard CC et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. *N Engl J Med* 2016; 375: 443–53
29. Cancer Genome Atlas Research Network. The Molecular Taxonomy of Primary Prostate Cancer. *Cell* 2015; 163: 1011–25
30. Robinson D et al. Integrative Clinical Genomics of Advanced Prostate Cancer. *Cell* 2015; 162: 454
31. Taza F et al. Differential activity of PARP inhibitors in BRCA1- versus BRCA2-altered metastatic castration-resistant prostate cancer (mCRPC). *J Clin Ortho.* 2021; 39: 100
32. Shi Z et al. Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC). *J Clin Orthod* 2020; 38: 182
33. Espiritu SMG et al. The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression. *Cell* 2018; 173: 1003–1013.e15
34. Abida W et al. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. *J Clin Oncol* 2020; 38: 3763–72
35. Merseburger AS et al. Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. *Eur Urol* 2021. doi:10.1016/j.eururo.2020.12.039
36. ClinicalTrials.gov NIH U.S. National Library of Medicine. [cited 22 Jun 2021]. Available: <https://clinicaltrials.gov/ct2/show/NCT02952534?term=BRCA&cond=mCRPC&gndr=Male&draw=2&rank=10>